SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools
Data Mining and In Silico modelling
WP5 aims at:
Designing softwares that support biomarker discovery.
Providing tools for information retrieval in -omics databases, for organizing and navigating phenotypic data and for mining literature on proteins, lipids and metabolites.
Designing predictive models of diabetes complications based on phenotypic measurements and candidate biomarkers emerging from all SUMMIT work packages. Different modelling strategies such as SVMs and Bayesian Networks are being exploited to rank the genes and biomarkers from the datasets as biologically plausible candidate biomarkers.
Exploiting the in silico probabilistic models of diabetes complications to evaluate the impact of the candidate markers as surrogate endpoints in clinical trials and their effectiveness in drug registration trials.
Work Package 5 (WP5)
To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
the identification of patients at high risk of diabetes complications
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.